Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by H. Mukai
Total Records ( 2 ) for H. Mukai
  H. Mukai
 

Targeted drugs against breast cancer are being developed centering around ones targeting HER2. In addition to trastuzumab and lapatinib that were already approved in Japan, promising drugs are being developed one after another. Basic mechanisms of their action and resistance emergence are being clarified step by step. In consideration of extraordinarily high medical expenditures of targeted drugs compared with conventional cytotoxic anticancer agents, it is critical to choose a targeted drug from a standpoint that it has definitely different features besides high efficacy and it has predictive factors which enable accurate anticipation of effects or adverse events. It will be confusing for the time being how each targeted drug is used properly in terms of the prescription order or combinations with chemotherapy. Over the middle- or long-term, clinical trials comparing these drugs will be conducted until clinically effective and easy-to-use targeted drugs in a true sense survive. Clinical handling of targeted drugs is not easy if conducted in the conventional way. Whereas conventional cytotoxic anticancer agents have major adverse events like nausea/vomiting or myelosuppression in common, such a variety of side effects occur in the use of targeted drugs as vary greatly according to different mechanisms of action of individual drugs. Oncologists will be required to master appropriate initial therapy to treat them; on the other hand, oncologists need to cooperate with specialists in other fields more than they used to.

  H. Higashino , M. Tabuchi , S. Yamagata , T. Kurita , H. Miya , H. Mukai and Y. Miya
  Since Nitric Oxide (NO) is produced by three types of Nitric Oxide Synthases (NOSs), rapid changes in stable oxidized metabolites (nitrite and nitrate, NOx) in the tissues and blood should be represented by the amount of stable forms in serum and may reflect vascular activities and circulatory or inflammatory changes in the body. Therefore, serum NOx levels in patients with various diseases were measured and compared to healthy controls. Four hundred and sixty five in- and outpatients aged 14 to 96 years were included in this study and 49 healthy hospital workers were included in the control group. The NOx levels of both groups were measured at rest in the morning using an ozone chemiluminescence method. When compared with the control group, serum NOx levels were higher in patients consist of around 40 or more in numbers diagnosed with cardiovascular diseases including myocardial infarction, hyperlipaemia, gastrointestinal diseases including acute enteritis, chronic liver diseases including viral B and C type hepatitis and liver cirrhosis, diabetes in males, hypertension with comorbid diseases. In addition, patient groups with renal disorders, hyperuricemia, osteoporosis, untreated cancers, autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) were also higher, although the each number might be not enough to compare between the groups. Patient groups with acute and chronic inflammation had significantly higher serum NOx levels. Therefore, measurement of serum NOx in patients may be useful for understanding the status and pathophysiology of inflammatory diseases and those in which inflammation is a component.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility